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CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo Leukemia (2015) 29, 1437-1441; doi:10.1038/leu.2015. 10 MYC dysregulation confers a poor prognosis to diffuse large B-cell lymphoma (DLBCL), and effective therapeutic strategies are lacking in relapsed/refractory DLBCL, Burkitt lymphoma and intermediate forms. 1, 2 As a master transcriptional regulator, MYC recruits transcription complexes containing RNA polymerase II (Pol II) to facilitate effective transcriptional elongation of MYC gene targets. 3 Pol II is fully activated by phosphorylation of a critical serine residue at position 2 within heptapeptide repeats in the carboxy-terminal domain (CTD), a function performed by the positive transcription elongation factor b (P-TEFb; comprising CDK9 and cyclin T1). 4 It has been shown that MYC binds and recruits P-TEFb to its targets as a means to activate Pol II. 3, 5, 6 More recently, CDK9-mediated transcriptional elongation was reported as essential for tumor maintenance in a genetically defined MYC-driven model of hepatocellular carcinoma. 7 Thus, CDK9 dependence may represent a druggable vulnerability in lymphomas with dysregulated MYC expression.
Dinaciclib (Merck, Boston, MA, USA) is a novel CDK inhibitor that has reached phase 1b/2 of clinical trials for a range of solid-organ malignancies, as well as for myeloma and chronic lymphocytic leukemia. 8 We hypothesized that CDK9 inhibition by dinaciclib would represent a rational pharmacologic approach to target the transcription of critical MYC-regulated oncogenic effector proteins. Here we describe durable in vivo responses to dinaciclib in aggressive MYC-driven lymphoma, mediated by downregulation of Pol II-mediated Mcl-1 transcription.
Dinaciclib has 50% kinase inhibitory concentrations of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. null mice transplanted with human IG-cMYC-translocated BL-41.luc2 lymphoma 3 days before the commencement of the therapy with 20% HPBCD vehicle or 30 mg/kg dinaciclib by intraperitoneal injection twice weekly. Mice were imaged at 7 and 14 days post transplantation. (g) Overall survival of the mice from the experiment is described in f. Gray shading denotes the period of therapy. The median survival for vehicle and dinaciclib-treated mice were 19 and 26 days, respectively (P o0.001).
As Bcl-2 and Mcl-1 have been implicated as important apoptotic regulators in Eμ-Myc lymphomas, 9, 10 we assessed the effects of dinaciclib on these proteins. We hypothesized that CDK9 inhibition with dinaciclib would target Mcl-1 transcription, as has been observed with other CDK inhibitors in myeloma and mantle cell lymphoma. 11, 12 Eμ-Myc and human IG-cMYC-translocated cell lines were treated with dinaciclib or dimethylsulfoxide control and interrogated using the quantitative PCR analysis for the effect on Mcl-1 and Bcl-2 mRNA. Dinaciclib treatment was associated with a significant reduction in Mcl-1 mRNA, with no significant effect on Bcl-2 transcript levels (Figure 1c, Supplementary Figure S2) . The in vivo efficacy of dinaciclib was then assessed by transplanting the same Eμ-Myc lymphomas into cohorts of syngeneic C57Bl/6 recipients. Compared with the vehicle control, dinaciclib treatment was well tolerated and associated with a highly significant survival advantage of tumor-bearing mice, including those bearing a p53-null lymphoma and a lymphoma with a spontaneous p53 mutation encoding a dominant-negative p53 protein (Figures 2a-c, Supplementary Figure S3) . In contrast, dinaciclib-mediated therapeutic efficacy was severely attenuated in isogeneic p53-competent Eμ-Myc lymphoma overexpressing Mcl-1 (Figure 2d) . In separate experiments, mice bearing transplanted Eμ-Myc cells were left untreated for 12 days to establish bulky nodal disease, at which time they received a single dose of dinaciclib or vehicle 1 or 4 h before being killed and before the lymph nodes were harvested. Consistent with the in vitro data, lymph node protein lysates showed reductions of pRpb1 and total Mcl-1 protein (Figure 2e) , concomitant with the induction of apoptosis (Supplementary Figure S4) . Finally, dinaciclib treatment of immunocompromised mice xenografted with the human IG-cMYC-translocated lymphoma was associated with reduced disease progression and significantly prolonged overall survival (Figures 2f and g ).
In conclusion, our findings indicate that CDK9 inhibition by dinaciclib is highly effective in aggressive MYC-driven lymphomas, including 'poor-risk' p53-deficient clones, via selective inhibition of critical MYC targets including Mcl-1 (which is currently undruggable with existing BH3 mimetics). 13, 14 Our data suggest a linear and druggable dependency between MYC and Mcl-1 that is contingent on CDK9 signaling. These findings are of particular interest in the context of a recent publication by Kelly et al., 15 further highlighting the dependency of MYC-driven B-cell lymphoma to Mcl-1. Rapid clinical translation of CDK9 inhibitors to MYC-dysregulated lymphoid malignancy should now be considered. Despite the advent of bortezomib, thalidomide and lenalidomide, relapse of multiple myeloma (MM) is common, and novel therapies are needed urgently. 1 Interactions of MM cells with bone marrow (BM) accessory and immune effector cells inhibit antitumor immunity as well as induce MM growth, survival and drug resistance. 1 For example, we showed that plasmacytoid dendritic cells (pDCs) are increased in the BM of MM patients compared with normal BM, and these contribute to immune dysfunction, as well as promote tumor cell growth and survival. 2 Aberrant pDCs' function in MM is evidenced by their interaction not only with MM cells but also with immune effector T cells: MM BM pDCs have decreased ability to trigger T-cell proliferation compared with normal pDCs. 2 Dysfunctional T cells and natural killer (NK) cells in MM 3, 4 together with functionally defective pDCs 2 confer immune suppression in MM. To date, the mechanism(s) and the role of immunoregulatory molecules mediating pDC-T cell and pDC-NK cell interactions in MM remain undefined. Here we extended our previous studies 2, 5 to examine the role of immune checkpoint receptor programmed cell death protein 1 (PD1) and its ligand PDL1 in pDC-T cell and pDC-NK cell interactions in the MM BM milieu, and to determine whether this interaction represents a therapeutic target to restore antitumor immunity and cytotoxicity. PD1 (CD279), a member of the CD28 family of receptors, is expressed on the surface of antigen-activated and -exhausted T cells.
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4 PD1 has two ligands, PDL1 (B7-H1; CD274) and PDL2 (B7-DC; CD273). Although PDL1 expression has not been observed in normal epithelial cells, it is highly expressed on many solid tumors.
6 PDL2 is more broadly expressed on normal healthy tissues than PDL1. The physiological role of PD1 is to maintain T-cell homeostasis by restricting T-cell activation and proliferation, thereby preventing autoimmunity. Importantly, the interaction of PD1+ T cells with PDL1-expressing cells inhibits T-cell responses. [7] [8] [9] In the context of MM, studies have demonstrated PD1-expressing T cells and NK cells in the MM BM milieu, as well as PDL1 on MM cells. 3, [10] [11] [12] [13] However, the expression of PDL1-PD1 on MM patient-derived pDCs and its functional significance during pDC-MM-T-NK cell interactions remain undefined.
We first analyzed freshly isolated MM cells, pDCs and T cells from MM patient BM samples (n = 11) for PDL1 and PD1 expression using flow cytometry (fluorescence-activated cell sorter (FACS)). Both MM cells and pDCs expressed high surface levels of PDL1, whereas T cells showed high PD1 levels (Figures 1a-c) . No significant PDL1 expression was noted on normal BM plasma cells. Our findings are consistent with previous reports showing that MM cells, but not normal plasma cells, express PDL1. 3, [10] [11] [12] [13] These data indicate that the interactions between PDL1-expressing MM cells and pDCs with PD1-positive T cells may contribute to both T-cell and pDC immune dysfunction in MM, and MM cells may escape antitumor immunity by virtue of PDL1 expression.
We next examined whether blockade of PDL1-PD1 restores anti-MM immune response and/or affects pDC-induced MM cell growth, using a monoclonal antibody (Ab) specifically directed against PDL1. A recent study analyzed the expression of PD1 and PD1-ligands in the tumor immune microenvironment and demonstrated clinical responses to anti-PD1 Ab therapy in PDL1-positive tumors.
8 PDL1 is expressed in both pDCs and MM cells, including relapsed or refractory MM, 13 and we hypothesize that blockade of PDL1 will alleviate T-cell immune suppression conferred by both MM cells and pDCs during pDC-MM-T cell interactions. Moreover, as PDL1 binds not only to PD1 but also to CD80, on T cells to induce T-cell inhibition, 14 anti-PDL1 Ab may block both co-inhibitory signals on T cells. Preclinical and clinical studies have begun to examine the utility of anti-PDL1 monoclonal Ab in MM. 10, 11, 15 Here we targeted PDL1 rather than PDL2 for the following reasons: (1) PDL1 is more restricted in its expression on normal tissues than PDL2, and targeting PDL1 may therefore cause less on-target off-tissue toxicity; 9 (2) a recent report correlated PDL1, but not PDL2, expression with response to anti-PD1 therapy; 8 and (3) we found that both pDCs and MM cells express variable and low levels of PDL2 versus PDL1.
We first examined whether blockade of PDL1 affects the ability of pDC to induce MM cell growth. The patient MM cells or MM cell lines (MM.1S, MM.1R and RPMI-8226) were cultured either alone or together with MM-pDCs in the presence or absence of anti-PDL1 Ab for 72 h, followed by analysis of growth. pDCs triggered proliferation of autologous MM cells and MM cell lines, as in our previous studies. 2, 5 Importantly, anti-PDL1 Ab did not significantly inhibit pDC-triggered growth of MM cells (Figure 1d and Supplementary Figure 1) . Our recent study showed that targeting toll-like receptor-9 blocks pDC-induced MM cell growth, 2,5 which served as a positive control in these studies (Figure 1d and Supplementary Figure 1) . Although blocking PDL1 does not affect pDC-induced MM cell growth, pDC-MM cell interactions upregulate PDL1 expression on both cell types, consistent with earlier observations that BM stromal cells induce PDL1 expression on MM cells. 13 Such interactive mechanisms enhancing PDL1 expression in the MM BM milieu further abrogate PD1-expressing T-cell Accepted article preview online 24 February 2015; advance online publication, 24 February 2015
